Clinical trial NCT00305435 - References

Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) — Safety Study of AMG 531 in Japanese Subjects With ITP

Citation(s)

•   Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, Iwato K, Ohtsu T, Berger DP
  A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009 Sep;90(2):157-65. doi: 10.1007/s12185-009-0361-y. Epub 2009 Jun 20.

An Open Label Phase 2 Study Evaluating the Safety of Starting Dose of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Details for clinical trial NCT00305435